| Breakdown | TTM | Mar 2025 | Sep 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.50M | 38.90M | 56.20M | 73.10M | 82.50M | 85.80M |
| Gross Profit | 11.80M | 14.80M | 19.60M | 20.90M | 27.60M | 22.50M |
| EBITDA | 15.10M | 16.40M | 7.50M | 6.90M | 15.80M | -10.50M |
| Net Income | 6.30M | 6.20M | 3.30M | -100.00K | 12.10M | -21.50M |
Balance Sheet | ||||||
| Total Assets | 26.30M | 28.70M | 22.40M | 30.60M | 36.80M | 35.60M |
| Cash, Cash Equivalents and Short-Term Investments | 3.00M | 4.30M | 5.00M | 7.10M | 9.20M | 6.90M |
| Total Debt | 8.80M | 8.80M | 19.90M | 20.00M | 20.20M | 20.40M |
| Total Liabilities | 36.40M | 38.10M | 52.50M | 32.40M | 35.30M | 78.60M |
| Stockholders Equity | -10.10M | -9.40M | -30.10M | -1.80M | 1.50M | -43.00M |
Cash Flow | ||||||
| Free Cash Flow | -2.60M | -1.50M | 2.50M | -800.00K | 2.70M | -4.40M |
| Operating Cash Flow | -2.60M | -1.50M | 4.80M | 1.50M | 5.60M | -4.00M |
| Investing Cash Flow | 15.50M | 14.80M | -2.30M | -2.30M | -2.90M | -400.00K |
| Financing Cash Flow | -12.60M | -14.00M | -4.50M | -1.20M | -500.00K | 5.20M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | £549.51M | 47.00 | 7.52% | ― | 13.21% | -54.35% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
61 Neutral | £25.94M | 2.81 | 63.08% | ― | -1.96% | 28.69% | |
60 Neutral | £16.32M | -18.59 | -5.63% | ― | -1.65% | -454.55% | |
60 Neutral | £625.44M | -3.49 | -18.75% | ― | -20.36% | 44.33% | |
56 Neutral | £683.79M | 15.48 | ― | 1.40% | 3.94% | ― | |
45 Neutral | £10.98M | 1.74 | ― | ― | -30.78% | 86.44% |
Mothercare has refinanced its existing debt by replacing an £8m facility with Gordon Brothers through a new special purpose vehicle backed by a consortium of investors, enlarging the facility to £8.46m at signing with scope to rise to £10m and extending maturity to December 2027. The amended facility, which carries a 25% annual coupon split between cash and payment-in-kind interest, remains technically in default and repayable on demand, but directors say the deal improves alignment between secured creditors and shareholders, even as Gordon Brothers is fully repaid and retains its warrants.
The company has also secured an extension to the deferral of annual pension deficit contributions of £3m per year to March 2027, pushing £6m of payments into a new schedule to be agreed by March 2027, with contributions resuming from April 2027 at an agreed affordable level. Chairman Clive Whiley said the combined refinancing and pension deferral ease material uncertainty, bolster liquidity, and provide flexibility to pursue international growth opportunities, underscoring management’s confidence that the strengthened capital structure can support a renewed push in both existing and new territories.
The most recent analyst rating on (GB:MTC) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Mothercare stock, see the GB:MTC Stock Forecast page.
Mothercare plc has disclosed significant share purchases by senior leadership, with chairman Clive Whiley increasing his beneficial interest from 8 million to 50 million shares through the acquisition of 42 million shares via the Zodiac Executive Pension Scheme, and chief financial officer Andy Cook acquiring 5 million shares. The transactions, executed on 23 December 2025 at 1.0p per share on the London Stock Exchange, materially raise insider ownership in the company, a move that may be interpreted by investors as a signal of management confidence in Mothercare’s prospects and alignment of executives’ interests with those of shareholders.
The most recent analyst rating on (GB:MTC) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Mothercare stock, see the GB:MTC Stock Forecast page.
Mothercare reported a sharp contraction in its interim performance for the 26 weeks to 27 September 2025, with worldwide franchise retail sales down 25% to £90.7 million, turnover nearly halved to £11.6 million and adjusted EBITDA falling to £0.8 million, leading to an adjusted operating loss of £0.5 million. The decline reflects store closures in the Middle East and its planned exit from Boots, but the group has materially reduced net debt to £5.8 million and is positioning itself as a smaller, cash-generative business. Chairman Clive Whiley highlighted significant progress on strategic partnerships, including a South Asian joint venture with Reliance Brands and a 10‑year licensing deal with Turkish specialist Ebebek, both designed to rebuild scale, expand store footprints and open new routes to market. With Reliance targeting rapid expansion and Ebebek bringing substantial buying and distribution power, Mothercare aims to use these alliances, alongside planned refinancing of its facilities, to reignite growth in global retail sales and restore its market presence following years of geopolitical and pandemic-related disruption.
The most recent analyst rating on (GB:MTC) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Mothercare stock, see the GB:MTC Stock Forecast page.